Effect of Vitamin D on Morbidity and Mortality of the COVID-19

• Status: Recruiting
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19).

Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias
• Collaborators: Hospital Universitario Central de Asturias; Instituto de Investigación Sanitaria del Principado de Asturias
• Treatments: Cholecalciferol; Vitamin D

Criteria

Inclusion Criteria:

• > 18 year

• Diagnosis of COVID-19

• Accept to participate in the study ( consent)

Exclusion Criteria:

• Pregnancy

• Allergy to vitamin D

• Consumption of any form of vitamin D during the last 3 months

• Expected fatal outcome in the next 24 hours

• Cognitive deterioration